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Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney
Function and Associated Cardiovascular Outcomes: Post Hoc
Analysis of 6 Double-Blind Randomized Controlled Trials
Liffert Vogt, MD, PhD; Sripal Bangalore, MD, MHA; Rana Fayyad, PhD; Shari Melamed, MD; G. Kees Hovingh, MD, PhD;
David A. DeMicco, PharmD; David D. Waters, MD
Background-—Kidney function decreases during the lifetime, and this decline is a powerful predictor of both kidney and
cardiovascular outcomes. Statins lower cardiovascular risk, which may relate to beneficial effects on kidney function. We studied
whether atorvastatin influences kidney function decline and assessed the association between individual kidney function slopes
and cardiovascular outcome.
Methods and Results-—Data were collected from 6 large atorvastatin cardiovascular outcome trials conducted in patients not
selected for having kidney disease. Slopes of serum creatinine reciprocals representing measures of kidney function change ([mg/
dL]1/y), were analyzed in 30 621 patients. Based on treatment arms, patients were categorized into 3 groups: placebo
(n=10 057), atorvastatin 10 mg daily (n=12 763), and 80 mg daily (n=7801). To assess slopes, mixed-model analyses were
performed for each treatment separately, including time in years and adjustment for study. These slopes displayed linear
improvement over time in all 3 groups. Slope estimates for patients randomized to placebo or atorvastatin 10 mg and 80 mg were
0.009 (0.0008), 0.011 (0.0006), and 0.014 (0.0006) (mg/dL)1/y, respectively. A head-to-head comparison of atorvastatin 10 and
80 mg based on data from 1 study (TNT [Treating to New Targets]; n=10 001) showed a statistically significant difference in slope
between the 2 doses (P=0.0009). From a Cox proportional hazards model using slope as a predictor, a significant (P<0.0001)
negative association between kidney function and cardiovascular outcomes was found.
Conclusions-—In patients at risk of or with cardiovascular disease, atorvastatin improved kidney function over time in a dose-
dependent manner. In the 3 treatment groups, kidney function improvement was strongly associated with lower cardiovascular risk.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00327418; NCT00147602;
NCT00327691. ( J Am Heart Assoc. 2019;8:e010827. DOI: 10.1161/JAHA.118.010827.)
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P atients with end-stage renal disease (ESRD) are atincreased risk of cardiovascular disease (CVD), and this
association between kidney function and cardiovascular
outcomes is also observed in patients with relatively normal
kidney function.1 The intricate interaction between the
development and progression of chronic kidney disease
(CKD) and CVD results from the fact that both share common
risk factors such as age, hypertension, diabetes mellitus, and
dyslipidemia. Kidney function decline due to these factors
usually displays a linear course over the years, and the grade
of kidney function decline has recently been demonstrated to
be useful as an independent risk factor for mortality, CVD,
and/or ESRD in both CKD and non-CKD populations.2-4
Because of its linearity, the slope visualizing the course of
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kidney function during a given time span—instead of single
kidney function measurements—provides additional informa-
tion. In addition, individual slopes include information about the
preceding course of kidney function and may therefore not
completely depend on the severity of kidney function impair-
ment at the baseline measurement of a study. Individual slopes
over time, therefore, are potentially an important predictor for
both CVD and kidney outcomes over the long run.5 Thus,
interventions that beneficially influence slope over time may
also reflect cardiovascular and renal protection at an early
stage, as has already been demonstrated with other kidney
protective agents such as inhibitors of the renin-angiotensin-
aldosterone system (RAAS).6 In patients with CKD, as in other
high-risk patients, statins have proven to exert a substantial
cardiovascular benefit.7,8 Whether this effect of statins is
partially attributable to an effect on kidney function is unknown.
Current evidence indicates that kidney-protective effects
of statins show a heterogeneous picture. Statins reduce, for
instance, biomarkers for kidney damage, including albumin-
uria,9,10 but not uniformly so.11 In addition, various controlled
trials show that statins are beneficial by inducing a smaller
estimated glomerular filtration rate (eGFR) reduction at the
end of the study,12,13 and other studies indicate that eGFR
may even improve.14-16 The heterogeneous effects may
depend on both the dose and type of statin used, as also
demonstrated by the recent PLANET trials in both diabetic and
nondiabetic CKD patients.11 In PLANET, rosuvastatin nega-
tively influenced kidney function, as expressed by decreased
eGFR and increased proteinuria, whereas atorvastatin
improved GFR without influencing proteinuria.11
We set out to address whether the high-potency statin,
atorvastatin, has an effect on age-related kidney function
decline during an observation period extending beyond
12 months and whether this effect is dose dependent. Finally,
we assessed whether the slopes of individual patients
predicted cardiovascular outcome measures.
Methods
Data-Sharing Statement
On request, and subject to certain criteria, conditions, and
exceptions (see https://www.pfizer.com/science/clinical-
trials/trial-data-and-results for more information), Pfizer will
provide access to individual deidentified participant data from
Pfizer-sponsored global interventional clinical studies con-
ducted for medicines, vaccines, and medical devices (1) for
indications that have been approved in the United States
and/or the European Union or (2) in programs that have
been terminated (ie, development for all indications has been
discontinued). Pfizer will also consider requests for the
protocol, data dictionary, and statistical analysis plan. Data
may be requested from Pfizer trials 24 months after study
completion. The deidentified participant data will be made
available to researchers whose proposals meet the research
criteria and other conditions, and for which an exception
does not apply, via a secure portal. To gain access, data
requestors must enter into a data access agreement with
Pfizer.
Post hoc evaluation for slopes of kidney function decline
was performed using serum creatinine values collected from
randomized patients from long-term cardiovascular outcome
randomized controlled trials (RCTs) with atorvastatin in which
slope analysis was not a predefined outcome (Table 1).17-25
Studies were eligible for inclusion when they were RCTs with
≥12 months of follow-up; included participants who were
older than 18 years; had >2 serum creatinine values
measured; and randomly assigned therapy with fixed doses
of atorvastatin or placebo. We excluded those studies that
were designed to investigate patients with predefined primary
kidney disease and/or ESRD. Because plasma creatinine
levels were collected only at 2 time points in the IDEAL
(Incremental Decrease in End Points Through Aggressive Lipid
Lowering) trial (in 8888 randomized post–myocardial-infarc-
tion patients),21 and 4D (German Diabetes and Dialysis Study)
included type 2 diabetes mellitus patients on dialysis,24 these
studies were excluded from the analysis. ALLIANCE (Aggres-
sive Lipid-Lowering Initiation Abates New Cardiac Events) data
were excluded because variable atorvastatin doses were used
in the active treatment arm.25 Three groups were formed, and
the data from individual subjects were pooled. To assess the
slope in placebo patients, the placebo arms from ASCOT
(Anglo-Scandinavian Cardiac Outcomes Trial), CARDS (Collab-
orative Atorvastatin Diabetes Study), SPARCL (Stroke
Clinical Perspective
What Is New?
• In this post hoc analysis of 6 double-blind randomized
controlled cardiovascular outcome trials comprising 30 621
patients at risk of or having cardiovascular disease, we
demonstrate that atorvastatin treatment improves kidney
function over time in a dose-dependent fashion.
• Kidney function improvement, regardless of treatment arm,
was associated with lower cardiovascular risk.
What Are the Clinical Implications?
• Our data suggest that both the cardio- and vasculoprotec-
tive efficacy of a pharmacological agent, such as atorvas-
tatin, is reflected by the course of kidney function over time,
indicating that this kidney-related parameter might repre-
sent a surrogate end point for long-term outcomes in
cardiovascular risk patients.
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Prevention by Aggressive Reduction in Cholesterol Levels), and
ASPEN (Atorvastatin Study for Prevention of Coronary Heart
Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus)
were pooled.17-19,22 To assess the slope in atorvastatin 80 mg,
the 80-mg arms from SPARCL, TNT (Treating New Targets),
and SAGE (Study Assessing Goals in the Elderly) were
pooled.17,20,23 Additionally, data derived from the ASCOT,
CARDS, and ASPEN trials were pooled, and the slopes within
the 10-mg atorvastatin arm from these trials were
assessed.18,19,22 For TNT, which included 10 001 randomized
coronary artery disease patients, a formal comparison of the
10-mg dose versus the 80-mg dose was performed.20
All participants gave written informed consent before
enrollment. All studies were approved by the appropriate local
research ethics committee and performed in accordance with
the Declaration of Helsinki of the World Medical Association.
All data were processed anonymously.
Outcome Measures
The primary outcome was the slope of kidney function as
measured by the reciprocal of the serum creatinine level.2,26
The reciprocal of the serum creatinine level has a linear
relationship with the GFR, unlike the serum creatinine level,
which has a curvilinear relationship. These values, expressed
as (mg/dL)1, approximate GFR values, with which most
clinicians are familiar. In addition, equations from the Chronic
Kidney Disease Epidemiology Collaboration that are adjusted
for ethnic group were used to determine the estimated GFR
and eGFR slopes over time. Finally, the proportion of patients
who reached an eGFR decline of >30%—a recently advocated
surrogate for long-term renal outcomes—was calculated.4
Furthermore, the proportion of major cardiovascular events,
cardiovascular mortality, and all-cause mortality were
assessed. A major cardiovascular event was defined as major
coronary event (death from coronary heart disease, nonfatal
myocardial infarction, or resuscitation after cardiac arrest), fatal
or nonfatal stroke, major cardiovascular event (stroke plus any
major coronary event), acute coronary event (major coronary
event or unstable angina), any coronary event (acute coronary
event, unstable angina, or angina or ischemia requiring
emergency hospitalization). Cardiovascular mortality was
defined as death from coronary heart disease, fatal myocardial
infarction, fatal stroke, or other cardiovascular death.
Statistical Analyses
To determine the slope for the 3 pooled arms, a mixed model
was run separately for each treatment pooling with time of
assessment as a random effect and with adjustments for
study; all per-patient creatinine data were included in the
model, starting from baseline. Additionally, homogeneity of
slopes in the studies within each pooling was tested by adding
study9time of assessment to the mixed model. The slopes
were also computed for each of the 3 pooled arms with
adjustments for study, age, sex, body mass index, plasma low-
density lipoprotein (LDL) cholesterol, systolic blood pressure
(BP), diastolic BP, baseline RAAS inhibitor use, baseline aspirin
use, diabetes mellitus, smoking, history of CVD, diuretics use,
and hypertension. To compare the 10-mg slope to the 80 mg
slope, only TNT data were used because in this study subjects
were randomized to 10 mg versus 80 mg. This mixed model
included treatment, time of assessment, and treatment by
time interactions. In additional models, adjustments for (1)
number of creatinine measures; (2) age and sex; and (3)
change in LDL at month 3 from baseline were made for the
slope calculations. Slopes from the mixed model are
presented as estimate (standard error [SE]).
To evaluate the impact of individual 1/creatinine slopes on
cardiovascular events, a Cox proportional hazards model was
Table 1. Overview of Atorvastatin RCTs Included in This Analysis
Study17-25
No. of
Patients Clinical Condition Treatment Arms
FU
Duration, y
Time Points of Serum
Creatinine Sampling
ASCOT 10 305 Hypertension without CHD Atorvastatin 10 mg vs placebo 3.1 Baseline, mo 6, y 1, y 2, y 3, y 4
CARDS 2838 Type 2 diabetes mellitus without CHD Atorvastatin 10 mg vs placebo 3.8 Baseline, y 1, y 2, y 3, y 4
ASPEN 2410 Type 2 diabetes mellitus with/without CHD Atorvastatin 10 mg vs placebo 4.0 Baseline, y 1, y 2, y 3, y 4
SPARCL 4731 Stroke or transient ischemic attack Atorvastatin 80 mg vs placebo 4.5 Baseline, y 1, y 2, y 3, y 4, y 5, . . .
TNT 10 001 CHD and LDL-C <130 mg/dL Atorvastatin 80 mg vs
atorvastatin 10 mg
4.9 Baseline, y 1, y 2, y 3, y 4, y 5, . . .
SAGE* 893 Elderly (65-85 y) with documented
transient myocardial ischemia
Atorvastatin 80 mg vs
pravastatin 40 mg
1.0 Baseline, mo 3, y 1
ASCOT indicates Anglo-Scandinavian Cardiac Outcomes Trial; ASPEN, Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus;
CARDS, Collaborative Atorvastatin Diabetes Study; CHD, coronary heart disease; FU, follow-up; LDL-C, plasma LDL cholesterol; RCT, randomized controlled trial; SPARCL, Stroke
Prevention by Aggressive Reduction in Cholesterol Levels; SAGE, Study Assessing Goals in the Elderly; TNT, Treating New Targets.
*Only the atorvastatin treatment arm was included in the pooled analysis.
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used with 1/creatine slope as the predictor in the model.
Major cardiovascular events, cardiovascular deaths, and all-
cause mortality were assessed. Subjects without the event
were censored at their last clinical visit date or the last date
they were known to be alive, whichever was later. For major
cardiovascular events and cardiovascular death, subjects who
had died due to non-cardiovascular causes were censored on
the date of death. The Cox model included the slopes with
adjustments for each trial. Additionally, an adjusted Cox
model was run with adjustments for age, sex, body mass
index, plasma LDL, systolic BP, diastolic BP, baseline RAAS
inhibitor use, baseline aspirin use, diabetes mellitus, smoking,
history of CVD, diuretics use, and hypertension. These
analyses were performed for each treatment pooling sepa-
rately. Additionally, a sensitivity analysis was performed in
which slope was included as a quartile in the study-adjusted
Cox model.
Results
Patients
In the pooled analysis, individual data of 30 621 patients from
6 RCTs who were randomly assigned to either placebo
(10 057), atorvastatin 10 mg (12 763), or atorvastatin 80 mg
(7801), were analyzed. Median treatment duration was 3.9
(range: 1-4.9) years. Pooled demographic and baseline
characteristics of the 6 RCTs are given in Table 2 (for the
demographics of the 6 separate studies included see Tables
S1 through S6). Due to differences in disease conditions and
Table 2. Baseline Characteristics (Mean [SD]) of Pooled Treatment Arms
Placebo (N=10 057) Atorvastatin 10 mg (N=12 763) Atorvastatin 80 mg (N=7801)
Sex (% male) 72.5 78.1† 74.1‡k
Age, y 62.6 (9.2) 61.9 (8.6)† 62.4 (9.8)¶
Ethnicity, %
Black 3.0 3.2 2.7#
Asian 1.7 1.6 0.8
White 93.1 93.4 94.0§
Other 2.3 1.8 2.5
BMI, kg/m2 28.4 (4.4) 28.7 (4.5)† 28.1 (4.5)†k
Systolic BP, mm Hg 151.7 (22.1) 145.9 (23.0)† 133.6 (18.2)†k
Diastolic BP, mm Hg 88.2 (12.2) 85.4 (12.5)† 79.1 (10.0)†k
Cholesterol, mg/dL 209 (31) 195 (33)† 189 (33)†k
HDL-cholesterol, mg/dL 50 (14) 49 (13)† 48 (12)†k
LDL-cholesterol, mg/dL 129 (28) 115 (29)† 111 (28)†k
Serum creatinine, mg/dL* 1.1 (0.5-3.3) 1.1 (0.5-3.8) 1.1 (0.6-4.4)†k
Reciprocal of serum creatinine, (mg/dL)1 0.91 (0.15) 0.89 (0.14)† 0.88 (0.15)†k
eGFR, mL/(min1.73 m2) 66.8 (13.0) 66.5 (12.7) 64.7 (12.9)†k
CKD (eGFR <60 mL/[min1.73 m2]), % 29.8 29.8 35.6†k
Hypertension, % 82.6 75.6† 57.2†k
History of cardiovascular event, % 17.3 46.2† 76.4†k
Diabetes mellitus, % 42.4 36.3† 15.9†k
Smoking, % 24.7 21.4† 14.7†k
Comedication, %
Diuretics 10.6 16.5† 26.5†k
RAASi 18.7 30.8† 48.2†k
Aspirin 27.4 45.3† 86.2†k
BMI indicates body mass index; BP blood pressure; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate
(according to the CKD-EPI formula); HDL, high-density lipoprotein; LDL, low-density lipoproteh; RAASi, renin-angiotensin-aldosterone system inhibitor.
*Median (minimum-maximum).
†P<0.0001, ‡P<0.05, §P<0.01 vs placebo.
kP<0.0001, ¶P<0.001, #P<0.05 vs atorvastatin 10 mg.
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study design, almost all baseline characteristics of the 3
groups, including sex, body mass index, systolic and diastolic
BP, reciprocal serum creatinine, plasma total, high-density
lipoprotein, and LDL cholesterol, hypertension, history of CVD,
and diuretic, RAAS inhibitor, and/or aspirin use, differed
significantly. Furthermore, in the atorvastatin 10-mg group,
age was significantly lower as compared with the placebo and
atorvastatin 80-mg groups. The atorvastin 80-mg group
contained a slightly but significantly lower number of subjects
from African descent as compared with the atorvastatin 10-
mg group and higher numbers of subjects of white descent as
compared to placebo. The presence of CKD at baseline was
higher and eGFR was lower in the atorvastatin 80-mg group as
compared with placebo and the atorvastatin 10-mg groups
(Table 2).
Outcomes
Slope of Kidney Function
The average annual change in kidney function (as assessed by
the estimate of the reciprocal of the serum creatinine level
based on a mean [SD] number of 4.7 [1.4] measurements)
from the mixed model, displayed a linear pattern over time, is
shown in Figure 1 and Figure S1. Patients randomized to
placebo and 10 mg and 80 mg atorvastatin had slopes
(estimate [SE]) of 0.009 (0.0008), 0.011 (0.0006), and 0.014
(0.0006) (mg/dL)1/y, respectively (P<0.0001 for each
group). In the adjusted models with adjustments for (1)
number of serum creatinine measures, (2) age and sex, and
(3) change in LDL at month 3 from baseline, the slopes did not
change. Additionally, slope9study interaction was tested to
assess homogeneity of slopes across the studies. The
study9slope interactions assessed in each of the 3 pooled
groups (atorvastatin 10 mg and 80 mg and placebo) were all
statistically significant, indicating differences in slopes among
the different studies (P<0.0005 in all groups). Overall, the
slopes were, however, all in the same direction. The fully
adjusted model had minimal impact on the values of the
slopes, where slopes (SE) for placebo, atorvastatin 10 mg,
and atorvastatin 80 mg were 0.008 (0.0007), 0.011 (0.0005),
and 0.014 (0.0006), respectively.
In order to perform a formal comparison between the
atorvastatin doses, the TNT data set was analyzed and
showed a significant dose effect of atorvastatin on average
annual change in kidney function. In the patients randomized
to atorvastatin 10 mg, the slope was significantly lower
(estimate [SE] of 0.012 [0.0007] (mg/dL)1) compared with
the slope observed in the 80-mg group (0.015 [0.0007] (mg/
dL)1, P=0.0009).
The eGFR slopes showed a similar pattern. Placebo and
10 mg and 80 mg atorvastatin had slopes (estimate [SE]) of
0.25 (0.068), 0.51 (0.054), and 0.78 (0.056) mL/(min1.73 m2)
per year, respectively (P=0.0002 for placebo and P<0.0001
for atorvastatin 10 mg and atorvastatin 80 mg). Again, the
adjusted models affected the slopes negligibly (data not
shown). These findings would roughly translate to an eGFR
increase of 1.3, 2.6, and 3.9 mL/(min1.73 m2) over a 5-year
period for placebo, atorvastatin 10 mg, and atorvastatin
80 mg, respectively. In the formal comparison using TNT data,
once again a dose effect could be observed (0.58 [0.065] and
0.86 [0.065] mL/(min.1.73 m2) in the atorvastatin 10- and
80-mg groups, respectively [P=0.003]).
To account for the influence of differences in the dropout
rate (ie, nonrandom effects) among the treatment arms within
the 6 RCTs, a sensitivity analysis was performed including on-
treatment creatinine measurements only. This analysis did not
influence the results.
Finally, the proportion of patients with a decrease of >30%
in eGFR from baseline to the last visit was calculated. The
percentage of patients with a decrease >30% were 2.5% (95%
CI 2.2% to 2.9%), 2.1% (95% CI 1.9% to 2.4%), and 2.0% (1.7%
to 2.4%) for the placebo, atorvastatin 10-mg group, and
atorvastatin 80-mg group, respectively.
Effect of Individual Kidney Function Slopes on
Cardiovascular Event Rate and Mortality
Figures 2 and 3 report the hazard ratios of the Cox
proportional hazard model to assess the effect of average
annual change in kidney function on major cardiovascular
events, cardiovascular deaths, and all-cause mortality. The
model adjusted according to study showed that for these
outcomes average annual change in kidney function was a
highly significant predictor. In the model with adjustments for
age, sex, body mass index, plasma LDL, systolic BP, diastolic
BP, baseline RAAS inhibitor use, baseline aspirin use, diabetes
mellitus, smoking, history of cardiovascular events at baseline
(ie, either a cardiovascular or cerebrovascular event), diuretics
Figure 1. Modeled slopes of reciprocal of serum creatinine
across the 3 groups (placebo [green], atorvastatin 10 mg [black],
and 80 mg [red]).
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use, and hypertension, average annual change in kidney
function was a significant predictor within both atorvastatin
groups for major cardiovascular events and cardiovascular
death. For all-cause mortality, the group treated with
atorvastatin 80 mg had the lowest hazard ratio for each SD
of kidney function slope. Hazard ratios for major cardiovas-
cular events when the highest quartile was compared with the
lowest quartile were 1.82, 2.00, and 1.56 for placebo,
atorvastatin 10 mg and atorvastatin 80 mg, respectively
(P<0.0001). When the slope of eGFR was used similar
findings were observed (data not shown).
Discussion
This large-scale post hoc analysis including individual data
from 6 long-term cardiovascular outcome trials demonstrates
that in patients at risk or with CVD, atorvastatin modestly
improves kidney function over time in a dose-dependent
manner. In addition, this analysis shows that kidney function
improvement is strongly associated with lower cardiovascular
risk independent of treatment, whereas a decrease in kidney
function is associated with worse cardiovascular outcome. For
each SD increment of slope of kidney function, we observed a
13% to 14% reduction in major cardiovascular events and
cardiovascular mortality while being treated with atorvastatin
(either 10 or 80 mg daily).
Our data therefore indicate that efficacy of cardiovascular
protection over the long term obtained with atorvastatin is
reflected by effects on the course of kidney function over
time. In addition, our results emphasize the bidirectional
connection between the cardiovascular system and the
kidneys (ie, the cardiorenal axis) in treating cardiovascular
disease. This implies that both CVD reduction and renopro-
tection are achieved by treating patients at risk or with CVD
with atorvastatin. Vice versa, a renoprotective strategy, as
represented by atorvastatin treatment according to our data,
translates into better cardiovascular risk management. In
daily clinical practice one may therefore consider incorporat-
ing kidney function trajectories as read out for the success of
cardiovascular risk management regimens, in addition to
control of traditional cardiovascular risk factors such as BP
and lipid goals. So far, no adequately powered RCTs have
tested the hypothesis that targeting the kidney function
change over time may represent a cardiovascular risk factor
subject to treatment.
Our results confirm the observations in other cohorts,
where kidney function was also found to display a linear
relationship over time. Somewhat surprisingly, the slopes in
all 3 cohorts had a positive direction. It is known from other
cardioprotective agents such as RAAS inhibitors that these
drugs protect against kidney function decline, but these
agents do not usually improve kidney function.6 Previous post
Figure 2. Effect of kidney function slope on cardiovascular (CV) outcomes and all-cause mortality
(unadjusted analysis). HR indicates hazard ratio.
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hoc analyses of 2 RCTs (TNT and SPARCL, which were also
included in the current analysis) have demonstrated that the
average of eGFR increased during follow-up under atorvastatin
treatment both in CKD and non-CKD patients.14,15 A limitation
of these 2 analyses was that during follow-up the number of
subjects declined, particularly in SPARCL.14 Therefore, non-
random effects might have explained the overall eGFR
increase, meaning that only the patients with better out-
come—those randomized to the most effective treatment arm
—remained in the trial, and those patients with worse eGFR
were dropouts. In keeping with this, a closer look at the data
from the post hoc analysis of SPARCL revealed that the eGFR
change from baseline was less exaggerated when the “last
observation carried forward” analysis, including all subjects
(ie, a total of 4393 instead of 2169 subjects with complete
eGFR data after 60-month follow-up), was performed.14
According to this analysis, eGFR remained stable in the
high-dose atorvastatin arm while eGFR declined in the placebo
group.14 Our study was able to test the robustness of the renal
results from the 2 previous post hoc analyses by combining all
6 outcome RCTs in which patients were randomized to
atorvastatin or control treatment and by analyzing slopes of
kidney function (using both reciprocal serum creatinine and
eGFR values) instead of mean eGFR values at follow-up visits.
Because of the presumed linearity of slopes when an adequate
number of creatinine values are used, the effect of atorvastatin
on kidney function decline is subject to differences in follow-
up duration and drop-out of patients to a much lesser extent.
Yet, in our analysis nonrandom effects related to the
protective effect of atorvastatin might have accounted for
eGFR improvement. We therefore performed additional sensi-
tivity analyses by including only serum creatinine data while
patients were still receiving the study drug, which gave very
similar results to the main analysis. The possibility that
nonrandom effects may have importantly influenced our
results seems therefore unlikely, particularly in regard to
comparisons among the 3 groups. Nonrandom effects may,
however, have been responsible for the positive slopes
observed in the patient group randomized to placebo.
Another explanation for improvement of kidney function
over time might relate to changes of muscle mass because
serum creatinine and eGFR (calculated by using serum
creatinine) depend on muscle mass. Reduction of muscle
mass, reflecting protein wasting, will lead to higher reciprocal
creatinine values and higher eGFR. Yet, loss of muscle mass is
usually associated with worse outcomes, which is in contrast
to our observation that positive slopes were associated with a
beneficial effect on cardiovascular outcomes.
Figure 3. Effect of kidney function slope on cardiovascular (CV) outcomes and all-cause mortality
(adjusted analysis). BMI indicates body mass index; DBP, diastolic blood pressure; HR, hazard ratio; LDL,
low-density lipoprotein; RAAS, renin-angiotensin-aldosterone system; SBP, systolic blood pressure.
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Finally, the dose-dependent increase of slopes during
atorvastatin therapy might relate to increments of creatine
kinase activity associated with statin use. High creatine
kinase activity may result in lower serum creatinine, higher
eGFR, and higher urinary creatinine excretion—parameters
that usually reflect increased muscle wasting. However, a
recent cohort study in 1801 CKD patients demonstrated that
high serum creatine kinase was not associated with more
rapid progression to ESRD.27 In this study high serum creatine
kinase was associated with more frequent use of statins, and
correction for this potential confounder did influence the
results. Therefore, both this study and our finding that a
positive slope was also present in the placebo group indicate
that muscle wasting does not seem not to be responsible for
the unexpected changes in reciprocal serum creatinine
slopes.
If changes in creatinine metabolism do not explain our
findings, the question arises as to what the slope increment
represents? CKD is associated with ventricular and vascular
remodeling. The remodeling effects can be reversed by statin
use, and that might in turn translate into better kidney
function. Progressive kidney function decline has been related
to subclinical atherosclerosis as well as to increased arterial
inflammation.28 Atorvastatin has been shown to reverse these
vascular alterations that contribute to elevated cardiovascular
risk.29 As a consequence, further decline of kidney function
might be prevented. Other possible mediators are oxidative
stress and renal microvascular changes, which contribute to
renal impairment but are beneficially influenced by statin
treatment.30 Of note, these direct effects, beyond lipid-
lowering efficacy, on the vasculature and the kidney might not
be present after treatment with all statins. The PLANET
studies showed a distinct effect of atorvastatin versus
rosuvastatin treatment.11 Whereas atorvastatin 80 mg
induced reduction of albuminuria and stabilization of eGFR,
rosuvastatin led to higher albuminuria and decrement of
eGFR.
Limitations
A number of limitations of our study need to be addressed.
First, ideally the presence of all 3 groups in an RCT would
have reduced the large heterogeneity of the baseline charac-
teristics, which was observed in our study due to the use of
different sets of studies. Heterogeneous effects across
studies on kidney function slope were observed, but the
slopes were all in the same direction, indicating that the effect
on kidney function was robust. Despite adjustments for
baseline characteristics in our analyses, differences in patient
characteristics among the trials might still explain to some
extent why the size of the effect on slope differed. Second,
the studies in this analysis included patients with preserved
kidney function and a low risk of development of ESRD.
Therefore, the changes in kidney function over time were very
small and, thus, of limited value in daily clinical practice. Third,
albuminuria is an important risk marker for progressive kidney
function decline, but in our analysis we could not evaluate
albuminuria effects over time because this was not system-
ically assessed within the included trials. Finally, for the same
reason, we were not able to handle time-varying covariates
that influence slopes such as improvement of BP control or
the introduction of RAS inhibitors in the follow-up the 6 RCTs.
In conclusion, our analysis shows that atorvastatin improves
kidney function over time in a dose-dependent manner (ie, 80-
mg versus 10-mg dose). In each of the treatment groups it was
shown that kidney function improvement is strongly associated
with lower cardiovascular risk. These data support the notion
that both the cardio- and vasculoprotective efficacies of a
pharmacological agent are reflected by the course of kidney
function over time. Although the changes were small, our data
also suggest that this kidney-related parameter, and not only
LDL-cholesterol lowering, might represent a surrogate end
point for long-term outcomes in cardiovascular risk patients.
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SUPPLEMENTAL MATERIAL 
 
 
 
  
Table S1. Baseline characteristics (mean (SD)) from ASCOT. 
  Placebo 
N= 5,093 
Atorvastatin 10 mg 
N= 5,121 
Sex (% males)  81.4 81.2 
Age (yrs)  63.2 (8.6) 63.2 (8.5) 
Ethnicity (%) Black 
Asian 
Caucasian 
Other 
2.5 
1.6 
94.6 
1.3 
2.8 
1.5 
94.6 
1.2 
BMI (kg/m2)  28.7 (4.6) 28.6 (4.7) 
Systolic BP (mmHg)  164.2 (18.0) 164.2 (17.7) 
Diastolic BP  95.0 (10.3) 94.9 (10.3) 
Cholesterol (mg/dL)  212 (30) 212 (30) 
HDL cholesterol (mg/dL) 51 (14) 51 (14) 
LDL cholesterol (mg/dL) 133 (28) 133 (28) 
Serum creatinine (mg/dL)* 1.1 (0.6-2.5) 1.1 (0.5-3.8) 
Reciprocal of serum creatinine (mg/dL)-1 0.92 (0.14) 0.92 (0.15) 
eGFR (mL/min/1.73 m2) 68.5 (13.0) 68.6 (13.0) 
CKD (eGFR <60 mL/min/1.73 m2)(%) 24.5 24.4 
Hypertension (%) 100 100 
History of CV event (%)  13.5 12.5 
Diabetes mellitus (%)  24.8 24.5 
Smoking (%)  30.5 31.3 
Co-medication (%) Diuretics 
RAASi 
Aspirin 
1.0 
0.8 
16.7 
0.8 
0.5 
16.5 
*Median (Minimum-Maximum. BP: blood pressure, eGFR: estimated glomerular filtration rate 
(according to the CKD-EPI formula), RAASi: RAAS inhibitor. 
 
 
 
  
Table S2. Baseline characteristics (mean (SD)) from ASPEN. 
  Placebo 
N= 1,199 
Atorvastatin 10 mg 
N= 1,211 
Sex (% males)  67.0 65.7 
Age (yrs)  61.0 (8.2) 61.1 (8.1) 
Ethnicity (%) Black 
Asian 
Caucasian 
Other 
6.2 
2.7 
84.3 
6.8 
6.7 
3.1 
84.1 
6.2 
BMI (kg/m2)  28.9 (3.8) 28.9 (3.7) 
Systolic BP (mmHg)  133.4 (16.5) 133.1 (16.8) 
Diastolic BP  79.1 (9.3) 78.7 (9.2) 
Cholesterol (mg/dL)  194 (30) 194 (31) 
HDL cholesterol (mg/dL) 47 (13) 47 (14) 
LDL cholesterol (mg/dL) 114 (26) 113 (25) 
Serum creatinine (mg/dL)* 1.1 (0.7-2.6) 1.1 (0.6-3.5) 
Reciprocal of serum creatinine (mg/dL)-1 0.90 (0.15) 0.91 (0.15) 
eGFR (mL/min/1.73 m2) 66.0 (12.9) 66.2 (12.7) 
CKD (eGFR <60 mL/min/1.73 m2)(%) 31.4 32.0 
Hypertension (%) 54.8 55.4 
History of CV event (%)  23.8 26.2 
Diabetes mellitus (%)  99.8 99.9 
Smoking (%)  12.8 12.1 
Co-medication (%) Diuretics 
RAASi 
Aspirin 
20.7 
35.0 
3.0 
20.5 
35.2 
2.5 
*Median ((Minimum-Maximum). BP: blood pressure, eGFR: estimated glomerular filtration rate 
(according to the CKD-EPI formula), RAASi: RAAS inhibitor. 
 
 
 
 
Table S3. Baseline characteristics (mean (SD)) from CARDS. 
  Placebo 
N= 1,406 
Atorvastatin 10 mg 
N= 1,426 
Sex (% males)  67.9 68.0 
Age (yrs)  61.8 (8.0) 61.5 (8.3) 
Ethnicity (%) Black 
Asian 
Caucasian 
Other 
2.8 
2.6 
94.0 
0.6 
1.8 
3.1 
94.5 
0.6 
BMI (kg/m2)  28.8 (3.5) 28.7 (3.6) 
Systolic BP (mmHg)  144.0 (16.1) 143.9 (15.9) 
Diastolic BP  82.8 (8.4) 82.7 (8.5) 
Cholesterol (mg/dL)  207 (34) 208 (34) 
HDL cholesterol (mg/dL) 55 (14) 54 (13) 
LDL cholesterol (mg/dL) 117 (31) 119 (30) 
Serum creatinine (mg/dL)* 1.1 (0.7-2.2) 1.1 (0.6-1.9) 
Reciprocal of serum creatinine (mg/dL)-1 0.89 (0.13) 0.89 (0.13) 
eGFR (mL/min/1.73 m2) 63.8 (11.3) 64.0 (11.2) 
CKD (eGFR <60 mL/min/1.73 m2)(%) 36.8 36.3 
Hypertension (%) 79.1 79.8 
History of CV event (%)  2.8 3.9 
Diabetes mellitus (%)  99.9 99.9 
Smoking (%)  22.9 21.5 
Co-medication (%) Diuretics 
RAASi 
Aspirin 
19.8 
43.7 
15.0 
18.1 
44.7 
15.7 
*Median ((Minimum-Maximum). BP: blood pressure, eGFR: estimated glomerular filtration rate 
(according to the CKD-EPI formula), RAASi: RAAS inhibitor. 
 
 
 
 
Table S4. Baseline characteristics (mean (SD)) from SAGE (atorvastatin 80 mg arm only). 
  Atorvastatin 80 mg 
N= 446 
Sex (% males)  68.8 
Age (yrs)  72.4 (5.1) 
Ethnicity (%) Black 
Asian 
Caucasian 
Other 
0.5 
0.2 
97.1 
2.2 
BMI (kg/m2)  27.4 (4.0) 
Systolic BP (mmHg)  139.4 (18.6) 
Diastolic BP  78.0 (8.9) 
Cholesterol (mg/dL)  226 (37) 
HDL cholesterol (mg/dL) 45 (12) 
LDL cholesterol (mg/dL) 148 (30) 
Serum creatinine (mg/dL)* 1.1 (0.7-1.9) 
Reciprocal of serum creatinine (mg/dL)-1 0.91 (0.16) 
eGFR (mL/min/1.73 m2) 61.5 (13.4) 
CKD (eGFR <60 mL/min/1.73 m2)(%) 46.2 
Hypertension (%) 66.4 
History of CV event (%)  92.2 
Diabetes mellitus (%)  22.4 
Smoking (%)  5.4 
Co-medication (%) Diuretics 
RAASi 
Aspirin 
23.5 
47.8 
86.8 
*Median ((Minimum-Maximum). BP: blood pressure, eGFR: estimated glomerular filtration rate 
(according to the CKD-EPI formula), RAASi: RAAS inhibitor. 
 
 
 
 
Table S5. Baseline characteristics (mean (SD)) from SPARCL. 
  Placebo 
N= 2,359 
Atorvastatin 80 mg 
N= 2,360 
Sex (% males)  59.1 60.3 
Age (yrs)  62.5 (11.3) 63.0 (11.2) 
Ethnicity (%) Black 
Asian 
Caucasian 
Other 
2.8 
0.6 
93.4 
3.2 
3.1 
0.6 
93.3 
3.0 
BMI (kg/m2)  27.4 (4.5) 27.5 (4.6) 
Systolic BP (mmHg)  138.4 (19.3) 138.9 (19.4) 
Diastolic BP  81.4 (10.6) 82.0 (10.7) 
Cholesterol (mg/dL)  212 (29) 211 (30) 
HDL cholesterol (mg/dL) 50 (14) 50 (14) 
LDL cholesterol (mg/dL) 134 (24) 133 (24) 
Serum creatinine (mg/dL)* 1.1 (0.5-3.3) 1.1 (0.7-4.4) 
Reciprocal of serum creatinine (mg/dL)-1 0.93 (0.16) 0.92 (0.16) 
eGFR (mL/min/1.73 m2) 65.4 (13.7) 65.1 (13.8) 
CKD (eGFR <60 mL/min/1.73 m2)(%) 36.3 35.4 
Hypertension (%) 61.4 62.3 
History of CV event (%)  30.9 28.8 
Diabetes mellitus (%)  16.9 16.7 
Smoking (%)  19.3 19.1 
Co-medication (%) Diuretics 
RAASi 
Aspirin 
20.7 
34.0 
70.4 
20.7 
35.7 
69.9 
*Median ((Minimum-Maximum). BP: blood pressure, eGFR: estimated glomerular filtration rate 
(according to the CKD-EPI formula), RAASi: RAAS inhibitor. 
 
 
 
 
Table S6. Baseline characteristics (mean (SD)) from TNT. 
  Atorvastatin 10 mg 
N= 5,005 
Atorvastatin 80 mg 
N= 4,995 
Sex (% males)  80.8 81.2 
Age (yrs)  60.9 (8.9) 61.2 (9.0) 
Ethnicity (%) Black 
Asian 
Caucasian 
Other 
3.1 
1.1 
94.1 
1.7 
2.7 
1.0 
94.1 
2.3 
BMI (kg/m2)  28.6 (4.7) 28.4 (4.5) 
Systolic BP (mmHg)  130.9 (16.8) 130.5 (16.8) 
Diastolic BP  78.1 (9.5) 77.8 (9.5) 
Cholesterol (mg/dL)  175 (24) 175 (24) 
HDL cholesterol (mg/dL) 47 (11) 47 (11) 
LDL cholesterol (mg/dL) 98 (18) 97 (18) 
Serum creatinine (mg/dL)* 1.2 (0.7-3.0) 1.2 (0.6-3.3) 
Reciprocal of serum creatinine (mg/dL)-1 0.87 (0.13) 0.86 (0.13) 
eGFR (mL/min/1.73 m2) 65.2 (12.5) 64.7 (12.3) 
CKD (eGFR <60 mL/min/1.73 m2)(%) 33.0 34.7 
Hypertension (%) 54.4 53.9 
History of CV event (%)  97.7 97.5 
Diabetes mellitus (%)  15.0 15.0 
Smoking (%)  13.4 13.4 
Co-medication (%) Diuretics 
RAASi 
Aspirin 
31.1 
56.7 
93.6 
29.5 
54.1 
93.8 
*Median ((Minimum-Maximum). BP: blood pressure, eGFR: estimated glomerular filtration rate 
(according to the CKD-EPI formula), RAASi: RAAS inhibitor. 
 
 
 
 
Figure S1. Reciprocal of serum creatinine for each individual patient across the 3 groups 
(placebo (green), atorvastatin 10 mg (black), and 80 mg (red)). 
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